ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2946

Large Scale Genetic Analysis in BehçEt Disease. Identification of Residues Associated in the HLA Class I Region and New Susceptibility Loci

Lourdes Ortiz Fernández1, Francisco David Carmona2, Marco Antonio Montes Cano3, José Raúl García Lozano3, Marta Conde Jaldón4, Norberto Ortego Centeno5, María Jesús Castillo Palma6, Gerard Espinosa7, Genaro Graña Gil8, Juan Sánchez Bursón Sr.9, María Rosa Juliá10, Roser Solans11, Ricardo Blanco Alonso12, Ana Celia Barnosi Marín13, Ricardo Gómez de la Torre14, Patricia Fanlo Mateo15, Mónica Rodriguez Carballeira16, Luis Rodriguez-Rodriguez17, Teresa Camps18, Santos Castañeda19, Juanjo J Alegre Sancho20, Javier Martín2 and María Francisca Gonzalez Escribano21, 1Instituto de Parasitología y Biomedicina "López-Neyra", CSIC, Granada, Spain, 2Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, 3Departament of Immunology, Hospital Universitario Virgen del Rocío (IBiS,CSIC,US), Sevilla, Spain, 4Immunology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, 5Systemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada, Spain, 6Department of Internal Medicine, Hospital Universitario Virgen del Rocío, Sevilla, Spain, 7Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, 8Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, 9Rheumatology, Hospital de Valme., Sevilla, Spain, 108Department of Immunology, Hospital Universitari Son Espases, Palma de Mallorca, Spain, 11Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, 12Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, 13Department of Internal Medicine, Complejo Hospitalario Torrecárdenas, Almeria, Spain, 14Departament of Internal Medicine, Hospital Universitario Central de Asturias, Asturias, Spain, 15Department of Internal Medicine, Hospital Virgen del Camino, Pamplona, Spain, 16Departament of Internal Medicine, Hospital Universitari Mútua Terrassa, Terrasa, Spain, 17Rheumatology Service, Hospital Clínico San Carlos, Madrid, Spain, 18Departament of Internal Medicine, Hospital Regional Universitario de Málaga, Málaga, Spain, 19Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain, 20Department of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain, 21Hospital Universitario Virgen del Rocío (IBiS,CSIC,US), Sevilla, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Behcet's syndrome and genetics

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Vasculitis - Poster III: Rarer Vasculitides

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Behçet’s disease (BD) is a complex immune-mediated vasculitis which aetiology remains unknown although some evidences suggest that certain infectious agents and environmental factors may trigger the disease in genetically predisposed individuals. The HLA class I genes are the most important genetic factors in BD although other genes are also involved in the susceptibility to this pathology. To improve the current knowledge of its genetic background, we conducted the first large-scale genetic analysis on Spanish population, with special focus in the HLA region.

Methods:  A discovery cohort comprising 278 BD cases and 1,517 unaffected controls were genotyped using the Immunochip platform which is a custom high-density array that allows the analysis of 196,524 genetic variants across 186 known susceptibility loci for autoimmune and autoinflammatory disorders. We also imputed HLA data with a previously validated imputation method to perform a more comprehensive analysis of this genomic region. The validation step was performed on an independent replication cohort composed of 130 BD cases and 600 additional controls.

Results: The strongest association signals were observed in the HLA class I region, being HLA-B*51 the highest peak (overall P=6.82E-32, OR=3.82). A step-wise conditional logistic regression with classical alleles identified HLA-B*57 and HLA-A*03 as additional independent markers. The amino acid model that best explained the association, includes the position 97 of the HLA-B molecule and the position 66 of the HLA-A. Interestingly, these class I positions are located in the binding groove of their corresponding molecules. Among the non-HLA loci, the most significant in the discovery analysis were: IL23R (rs10889664: P=3.81E-12, OR=2.00), the JRKL/CNTN5 region (rs2848479: P=5.00E-08, OR=1.68) and IL12A (rs1874886: P=6.67E-08, OR=1.72), which were confirmed in the validation phase (JRKL/CNTN5 rs2848479: P=3.29E-10, OR=1.66; IL12A rs1874886: P=1.62E-08, OR=1.61).

Conclusion: Our results confirm HLA-B*51 as a primary-association marker in predisposition to BD and suggest additional independent signals within the class I region, specifically in the genes HLA-A and HLA-B. Regarding the non-HLA genes, in addition to IL-23R, previously reported in our population; IL12A, described in other populations, was found to be a BD susceptibility factor also in Spaniards; finally, a new associated locus was found in the JRKL/CNTN5 region.


Disclosure: L. Ortiz Fernández, None; F. D. Carmona, None; M. A. Montes Cano, None; J. R. García Lozano, None; M. Conde Jaldón, None; N. Ortego Centeno, None; M. J. Castillo Palma, None; G. Espinosa, None; G. Graña Gil, None; J. Sánchez Bursón Sr., None; M. R. Juliá, None; R. Solans, None; R. Blanco Alonso, None; A. C. Barnosi Marín, None; R. Gómez de la Torre, None; P. Fanlo Mateo, None; M. Rodriguez Carballeira, None; L. Rodriguez-Rodriguez, None; T. Camps, None; S. Castañeda, None; J. J. Alegre Sancho, None; J. Martín, None; M. F. Gonzalez Escribano, None.

To cite this abstract in AMA style:

Ortiz Fernández L, Carmona FD, Montes Cano MA, García Lozano JR, Conde Jaldón M, Ortego Centeno N, Castillo Palma MJ, Espinosa G, Graña Gil G, Sánchez Bursón J Sr., Juliá MR, Solans R, Blanco Alonso R, Barnosi Marín AC, Gómez de la Torre R, Fanlo Mateo P, Rodriguez Carballeira M, Rodriguez-Rodriguez L, Camps T, Castañeda S, Alegre Sancho JJ, Martín J, Gonzalez Escribano MF. Large Scale Genetic Analysis in BehçEt Disease. Identification of Residues Associated in the HLA Class I Region and New Susceptibility Loci [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/large-scale-genetic-analysis-in-behcet-disease-identification-of-residues-associated-in-the-hla-class-i-region-and-new-susceptibility-loci/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/large-scale-genetic-analysis-in-behcet-disease-identification-of-residues-associated-in-the-hla-class-i-region-and-new-susceptibility-loci/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology